#Opicapone as #levodopa adjunct cuts motor fluctuations in #Parkinson’s disease

Originally posted 2016-12-28 11:26:57.

Andrew J. Lees, M.D., from University College London, and colleagues enrolled 427 patients with PD receiving levodopa therapy who experienced signs of end-of-dose deterioration into a phase 3 trial. Participants were randomized to a 14- to 15-week placebo-controlled trial (129 received 25-mg/day opicapone, 154 received 50-mg/day opicapone, and 144 received placebo). Of the 376 patients who completed the double-blind phase, 286 completed a one-year open-label phase in which all patients received opicapone.

Esta entrada fue publicada en Sin categoría y etiquetada . Guarda el enlace permanente.

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *